A comprehensive overview of targeted therapy in metastatic renal cell carcinoma - Wikidata - wikimedia - TriplyDB

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

http://www.wikidata.org/entity/Q24606852

about

Broad targeting of angiogenesis for cancer prevention and therapy The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development Metastatic renal cell carcinoma without evidence of a primary renal tumour.Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts Increased Insulin mRNA Binding Protein-3 Expression Correlates with Vascular Enhancement of Renal Cell Carcinoma by Intravenous Contrast-CT and is Associated with Bone Metastasis.Breast cancer treatment and sulfotransferase.Nicotine induces alteration of H3K27 demethylase UTX in kidney cancer cell.Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?Cytoreductive nephrectomy in the era of targeted therapies: a review.Surgery for metastatic tumors of the pancreas Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?

P2860

Q27002903-87884210-F36C-409B-9D4F-21766C7A7B4E Q28076945-782F66D9-FB4D-40B1-ACB4-3290FF2DC57F Q33763962-0ABCCCA7-6747-495D-AB84-BD50A2A560C4 Q35063752-CFEC4590-9884-4CFE-8456-2D44CD23221C Q35194746-36095C12-1A02-4EA2-884E-1ED7BC6E9D4C Q36165534-AD9BFF12-B124-4EB8-8AE8-E73ECF5EE0FF Q38353775-4A464ED5-7720-458A-AA57-6B080E182698 Q39113692-FE4C9537-7883-4721-9D21-275D644DBC49 Q39120161-399C1101-BEE2-49E2-B795-792A70D9565B Q39216342-9E726E7E-DE46-4190-BED8-4CF09125C04C Q42141719-F89A365E-1BF3-4AFE-ABBB-DF57C7F73844 Q43095673-6797B647-81E5-4404-9637-D9AB7559D163

P2860

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

http://www.wikidata.org/entity/Q24606852

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@ast

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@en

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@nl

type

label

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@ast

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@en

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@nl

prefLabel

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@ast

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@en

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@nl

P1433

Q24606852-F0FEF483-1E19-4CFD-B54F-D4851C9C686A

P1476

Q24606852-77F34052-5F61-417B-87C9-4919B5CB7D81

P2093

Q24606852-55C6B9C9-3A38-456B-9DCA-F5FEEB03B5C2

Q24606852-7B5D7FD0-F83D-4B7B-8DFA-77836D6C903A

Q24606852-8A1F7529-FEE9-43AE-82EF-FB1638049B0F

Q24606852-B84A044E-454F-43D1-8924-2110D18BBE8F

P275

Q24606852-E15A3237-813B-4FBF-A3CF-FB7564098AEE

P2860

Q24606852-02E50260-086D-4DC2-A581-0A26AB63CA6C

Q24606852-033C212B-BEC4-4209-97AD-A7C75E44A3A1

Q24606852-073045CA-0708-4882-AD42-0A26D1EA63EA

Q24606852-088BA179-2F19-481C-901B-5D9B3EF6C77C

Q24606852-09B8995C-9CCD-4A4A-BF04-7D9EC92629E9

Q24606852-0AC7E35A-E546-4A5F-BC90-210AC650E1E4

Q24606852-0B9CB759-357A-45E4-A032-6FFC37DF5FA5

Q24606852-0C9EBF0B-82D4-42AD-912A-B9BA861B92FB

Q24606852-0E3CC749-B7E6-424B-9C6C-B3FBA8514AE9

Q24606852-0FC60173-7F27-4640-BB6E-10B4CC25D7B7

P304

Q24606852-09F26C40-8A1C-42E5-B2A6-284572325130

P31

Q24606852-4FCEA87D-2FF4-4853-A960-BD3F13D01BCD

Q24606852-6774149A-C698-4274-BE4B-E1ADD5E67C5A

P3181

Q24606852-9AD18DC6-A9B1-4483-9EEF-C400DD1D46E5

P356

Q24606852-AF2601CB-AF97-4F3D-A565-BC3DE6EE6E2C

P407

Q24606852-A8A5E71E-C59C-484F-ACAF-4B914DBE0774

P433

Q24606852-E267D5BB-FA4D-469F-8547-9CA9B521D230

P478

Q24606852-8D3CB1E3-CAFF-4E2E-BE73-6E49F67AAB25

P5008

Q24606852-59C4109A-38C5-4784-887E-383D2075A1AB

P577

Q24606852-AB71A49C-C170-439C-BF33-9E0C64F1018A

Q24606852-DA9AA9B4-8354-4784-B1A5-05D249E2FA45

P5875

Q24606852-45F27EB0-CD40-4962-AB92-9AF71E25EC8A

P698

Q24606852-8DBFA60F-78C8-4DC5-8EE2-3E4C225EE74B

P921

Q24606852-2173F1B7-92A9-419F-B8F7-9286E7264B27

Q24606852-9E0E05D5-8F7A-4095-BAF4-7A39D41FBA9E

Q24606852-EAC8719A-B7EF-4BAE-A004-7694B9F90493

Q24606852-F89DD8DC-2F5B-40DC-9278-6FF645759B92

P932

Q24606852-1A0FBBA3-3433-4F09-A525-2212C0771579

P3181

P356

156800912802429265

P1433

Current Cancer Drug Targets

P1476

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

@en

P2093

B Gyorffy

http://www.w3.org/2001/XMLSchema#string

P Surowiak

http://www.w3.org/2001/XMLSchema#string

Z Mihaly

http://www.w3.org/2001/XMLSchema#string

Z Sztupinszki

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

A quantitative analysis of kinase inhibitor selectivity

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

P304

857-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1636567

http://www.w3.org/2001/XMLSchema#string

P356

10.2174/156800912802429265

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224768012

http://www.w3.org/2001/XMLSchema#string

P698

22515521

http://www.w3.org/2001/XMLSchema#string

P921

renal cell carcinoma

kidney neoplasm

P932

3434473

http://www.w3.org/2001/XMLSchema#string